| Case Page

 | Case Page |

Case Page

 

Acadia Pharmaceuticals Inc.

Case Summary

Acadia Pharmaceuticals Inc. Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 08/13/2018 (Ongoing date of last review)

Filing Date: July 19, 2018

According to the Complaint, Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") is purportedly a biopharmaceutical company focused on the development and commercialization of medicines to address central nervous system disorders. The Company claims its lead drug is NUPLAZID (pimavanserin), which was approved by the FDA on April 29, 2016 for the treatment of hallucinations and delusions associated with PD Psychosis. The Company launched NUPLAZID in the United States in May 2016.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) that ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) that, as a result of the foregoing, Defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Company & Securities Information

Defendant: Acadia Pharmaceuticals Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ACAD
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

James Staublein, et al. v. Acadia Pharmaceuticals Inc., et al.

COURT: S.D. California
DOCKET #: 18-CV-01647
JUDGE: Hon. Roger T. Benitez
DATE FILED: 07/19/2018
CLASS PERIOD START: 04/29/2016
CLASS PERIOD END: 07/09/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Glancy Prongay & Murray LLP
    1925 Century Park East, Suite 2100 , Glancy Prongay & Murray LLP, CA 90067
    (310) 201-9150 (310) 432-1495 ·
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint for Violations of the Federal Securities Laws 07/19/2018
2 U.S. District Court Civil Docket 07/23/2018
 
 

Cases